Yang JS. Prognosis value of pituitary neuroendocrine tumor volume. World J Radiol 2025; 17(4): 106186 [DOI: 10.4329/wjr.v17.i4.106186]
Corresponding Author of This Article
Jian-She Yang, PhD, Academic Fellow, Chairman, Dean, Full Professor, Professor, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, No. 301 Yanchang Road, Shanghai 200072, China. 2305499@tongji.edu.cn
Research Domain of This Article
Clinical Neurology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Radiol. Apr 28, 2025; 17(4): 106186 Published online Apr 28, 2025. doi: 10.4329/wjr.v17.i4.106186
Prognosis value of pituitary neuroendocrine tumor volume
Jian-She Yang
Jian-She Yang, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China
Author contributions: Yang JS designed, wrote, and revised the letter.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jian-She Yang, PhD, Academic Fellow, Chairman, Dean, Full Professor, Professor, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, No. 301 Yanchang Road, Shanghai 200072, China. 2305499@tongji.edu.cn
Received: February 19, 2025 Revised: March 19, 2025 Accepted: April 11, 2025 Published online: April 28, 2025 Processing time: 63 Days and 3.2 Hours
Abstract
This study highlights the significance of considering pituitary neuroendocrine tumor volume when determining the appropriate line of therapy for patients with acromegaly. The findings suggest that, although tumor volume may assist in predicting the need for more aggressive treatment strategies, it is not a reliable indicator of disease persistence following surgical intervention. Further research is warranted to investigate additional factors influencing acromegaly treatment outcomes to enhance patient care.
Core Tip: Pituitary neuroendocrine tumor volume serves as a complementary prognostic factor for disease control in patients with acromegaly. Larger tumors are associated with a higher risk of persistent disease and an increased likelihood of requiring medical treatment following surgery. The consideration of tumor volume is essential in clinical decision-making when managing acromegaly.
